JMDC (4483) FY2026 Q3 Earnings Report

Quick View

Executive Summary

FY2026 Q3 cumulative results: Revenue 364.9B yen (YoY +23.2%), Operating Income 77.7B yen (+37.1%), Ordinary Income 73.1B yen (+32.3%), Net Income 48.2B yen (+23.8%). The company achieved strong double-digit growth across all profit levels, with operating income growing faster than revenue, indicating effective operating leverage. Gross profit margin maintained at a high 54.8% level, while operating margin reached 21.3%. Operating cash flow of 56.0B yen exceeded net income (OCF/NI ratio 1.16x), demonstrating solid cash-backed earnings quality. Total assets increased to 1,561.8B yen with equity ratio at 52.4%, maintaining stable capital structure. Q3 standalone quarter showed revenue of 134.1B yen (+21% QoQ) and EBITDA of 41.6B yen (+32% QoQ), confirming return to robust growth trajectory after Q2 deceleration.

Performance Drivers

Revenue growth of +23.2% YoY was primarily driven by the Health Big Data segment expansion (+26% YoY), particularly strong demand from pharmaceutical companies' sales and marketing domains (+30% YoY in data utilization transaction value, +43% YoY specifically in pharma sales/marketing). Medical provider-facing business also contributed significantly with +32% growth. The Telemedicine segment maintained steady growth at +5% YoY with high profitability. Operating income increased +37.1%, outpacing revenue growth due to improved operational efficiency and favorable business mix toward higher-margin services. The gross profit margin of 54.8% remained stable, while SG&A expenses grew at a slower rate than revenue, resulting in operating leverage effects. The gap between ordinary income (73.1B yen) and net income (48.2B yen) represents primarily corporate tax, with no material non-recurring items identified. This represents a "revenue up, profit up" pattern with accelerating profit growth, indicating strong business momentum and operational efficiency gains.

Segment Analysis

The Health Big Data segment is the core business, generating revenue of 316.3B yen (+26% YoY) and EBITDA of 85.8B yen (+32% YoY), with EBITDA margin of 27%. This segment accounted for approximately 87% of total revenue and was the primary driver of consolidated performance. Within this segment, Industry-facing data utilization grew +30% YoY, with pharmaceutical sales and marketing showing particularly strong growth at +43%. Medical provider-facing business expanded +32% YoY, while Insurer and Consumer-facing business grew +15% YoY, demonstrating balanced growth across all sub-segments. The Telemedicine segment contributed revenue of 48.6B yen (+5% YoY) and EBITDA of 18.4B yen (+6% YoY), maintaining exceptional profitability with EBITDA margin of 38%. Despite slower growth, this segment's high margin structure provides stable profit contribution. The core Health Big Data segment clearly drove both revenue and profit growth, with margin improvement from 26% to 27% YoY indicating successful execution of high-value-added service offerings and operational efficiency initiatives.

Key Metrics

Profitability: ROE 5.8% (based on DuPont analysis: Net Margin 13.2% × Asset Turnover 0.234 × Financial Leverage 1.89), Operating Margin 21.3% (industry-leading level), EBITDA Margin 26.5%, Net Profit Margin 13.2%. Cash Quality: OCF/Net Income 1.16x (healthy cash generation), FCF -21.4B yen (negative due to large investments). Investment: Total investments in investing activities 77.4B yen including subsidiary acquisitions 63.1B yen, intangible asset acquisitions 10.5B yen, and property/plant/equipment 4.1B yen, indicating aggressive growth investment phase. Financial Health: Equity Ratio 52.4%, Interest-bearing Debt 426.4B yen, Net Debt/EBITDA approximately 1.3x (manageable level), Short-term Borrowings 55.9B yen (+27.2% YoY). Asset Efficiency: Total Asset Turnover 0.234 (low due to goodwill 634.4B yen representing 40.6% of total assets), Accounts Receivable 199.9B yen with DSO approximately 200 days (collection efficiency requires improvement).

Cash Flow Analysis

Operating CF: 56.0B yen (1.16x of Net Income; cash-backed earnings confirmed). The positive spread over net income indicates high earnings quality, with working capital changes contributing favorably as accounts payable increased 42.9B yen. Investing CF: -77.4B yen, primarily consisting of subsidiary acquisitions 63.1B yen (strategic M&A execution), intangible asset acquisitions 10.5B yen (data platform and system investments), and property/plant/equipment 4.1B yen. These investments align with the strategic collaboration with electronic medical record providers announced in Q3 to build a dominant healthcare data infrastructure. Financing CF: -10.5B yen in dividend payments, +12.0B yen net increase in short-term borrowings. FCF: -21.4B yen (Operating CF 56.0B yen - CapEx approximated as tangible/intangible asset investments). Cash position: 302.4B yen in cash and equivalents provides adequate liquidity buffer. Cash generation: Operating cash generation is Strong, but overall liquidity Needs Monitoring due to aggressive investment posture and increasing short-term debt (cash/short-term liabilities ratio showing stress signals). The negative FCF is driven by strategic investments expected to generate future returns, though ROIC at 4.1% indicates returns have not yet fully materialized.

Earnings Quality

Ordinary vs Net Income: Ordinary income of 73.1B yen and net income of 48.2B yen show a difference of 24.9B yen (34.1% of ordinary income), primarily attributable to income tax expense with no material non-recurring items identified in the disclosed data. Non-operating income/expense impact is minimal relative to operating income, indicating earnings are driven predominantly by core business operations. Accruals: Operating CF of 56.0B yen exceeding Net Income of 48.2B yen (ratio 1.16x) demonstrates healthy accruals quality with no red flags. The positive accruals indicate working capital management is supporting cash generation, particularly through accounts payable increase. However, accounts receivable at 199.9B yen with DSO of approximately 200 days represents a significant working capital burden and collection risk that warrants monitoring. Overall earnings quality is assessed as High for current period, with strong cash backing and operating-driven profits, though the extended receivables collection period is a structural concern requiring improvement.

Guidance Update

Full-year guidance: Revenue 505.0B yen, Operating Income 115.0B yen, Net Income 75.0B yen. Q3 cumulative progress rates: Revenue 72.3% (364.9B/505.0B), Operating Income 67.5% (77.7B/115.0B), Net Income 64.3% (48.2B/75.0B). Against standard quarterly progression (Q3 cumulative = 75%), revenue is tracking 2.7pt below, operating income is 7.5pt below, and net income is 10.7pt below standard pace. However, Q3 standalone quarter showed strong acceleration with revenue 134.1B yen and EBITDA 41.6B yen, representing sequential growth of +21% and +32% respectively from Q2. Management commentary indicates the business has returned to robust growth trajectory after Q2 deceleration, with strong momentum in pharmaceutical sales/marketing domain, recovering trends in medical domain and life insurance business, and steady expansion in insurer/consumer and medical provider domains. Given Q4 is typically the strongest quarter for the business and current momentum, full-year guidance achievement appears feasible, though operating income and net income will require Q4 acceleration to reach targets. Key factors for guidance achievement include: sustained pharmaceutical domain demand, medical domain order intake conversion, and continued operational efficiency gains.

Shareholder Returns

Year-end dividend of 16.00 yen per share has been determined. Based on full-year EPS forecast of 113.2 yen, the implied full-year dividend payout ratio is approximately 14.1%. Using Q3 cumulative net income of 48.2B yen and EPS of 73.58 yen, the annualized payout ratio approximates 21.8%. Dividend sustainability is Strong given the conservative payout ratio and operating cash flow of 56.0B yen substantially covering the dividend payment of 10.5B yen (OCF coverage 5.4x). However, FCF is negative at -21.4B yen due to aggressive investment activities, resulting in FCF dividend coverage of -2.05x. The company maintains cash and equivalents of 302.4B yen, providing ample buffer for dividend continuation. No share buyback activity is disclosed in the current period. Total shareholder return policy is not explicitly stated, but the low payout ratio suggests room for future dividend growth as investments mature and FCF turns positive. Medium-term dividend sustainability depends on investment returns (ROIC improvement) and FCF recovery, though near-term risk is minimal given strong operating cash generation and cash reserves.

Catalysts

Near-term: (1) Q4 performance delivery toward full-year guidance achievement, particularly operating income and net income acceleration needed to close the gap to targets. (2) Pharmaceutical sales and marketing domain demand continuation, with strong order intake momentum expected to translate into revenue in Q4. (3) Medical domain business recovery materialization, as order intake has been increasing and is expected to contribute to growth. (4) Life insurance business recovery from H1 softness continuing into Q4.

Long-term: (1) Strategic collaboration with electronic medical record providers to build dominant medical institution-derived data infrastructure, with contribution expected from FY2027 onward. (2) Generative AI adoption acceleration driving increased demand for objective data in hypothesis validation cycles. (3) Healthcare tech industry consolidation presenting partnership opportunities with truly valuable players. (4) Expansion of high-value-added consulting and data/AI solutions to pharmaceutical sales and marketing departments. (5) New data utilization initiatives including elderly data for insurers creating additional revenue streams. (6) ROIC improvement from past M&A investments (634.4B yen goodwill) as synergies materialize.

Industry Benchmark (Reference - Proprietary Data)

Industry Position (Reference - Proprietary Analysis)

Profitability: Operating Margin 21.3% vs. industry median 8.0% (significantly above median, top quartile performance), Net Profit Margin 13.2% vs. industry median 5.6% (above median), ROE 5.8% vs. industry median 8.2% (below median due to low asset turnover), ROIC 4.1% vs. industry median 16.0% (significantly below median, indicating capital efficiency challenge).

Growth: Revenue Growth YoY 23.2% vs. industry median 10.5% (above median, strong growth), EPS Growth 23.8% vs. industry median 30.0% (in line with industry).

Financial Health: Equity Ratio 52.4% vs. industry median 59.5% (slightly below median but healthy), Current Ratio calculation not available vs. industry median 2.13x.

Efficiency: Asset Turnover 0.234 vs. industry median 0.68 (significantly below median due to goodwill-heavy balance sheet), Receivables Turnover Days approximately 200 vs. industry median 60.53 days (collection efficiency significantly lags industry), Operating Working Capital Turnover Days elevated vs. industry median 45.15 days.

Cash Flow: OCF/Net Income 1.16x vs. industry median 1.40x (healthy but slightly below median), FCF Yield negative vs. industry median 6.0% (investment phase).

Summary: The company demonstrates industry-leading profit margins reflecting high-value-added business model, but capital efficiency metrics (ROE, ROIC, asset turnover) lag industry medians due to goodwill-heavy balance sheet from M&A strategy and extended receivables collection. Revenue growth exceeds industry median, positioning the company as a growth leader in the IT/Telecom sector. Financial health is adequate though equity ratio is modestly below median.

Industry: IT and Telecom (99 companies), Comparison: FY2025 Q3 period, Source: Proprietary analysis

Risk Factors

(1) Goodwill Impairment Risk: Goodwill of 634.4B yen represents 40.6% of total assets and 77.0% of equity. If acquired businesses fail to generate expected returns or market conditions deteriorate, material impairment losses could occur, significantly impacting earnings and equity. Current ROIC of 4.1% (vs. industry median 16.0%) suggests investment returns have not fully materialized, increasing impairment risk if performance does not improve.

(2) Accounts Receivable Collection Risk: Receivables of 199.9B yen with DSO approximately 200 days (vs. industry median 60.53 days) represents significant working capital burden and credit risk. Extended collection period constrains cash flow and increases exposure to customer credit events, particularly relevant given major customers include insurers, medical institutions, and pharmaceutical companies subject to regulatory and reimbursement changes. Quality alert flags indicate this as a material operational concern.

(3) Regulatory and Healthcare System Risk: Business model depends on healthcare data utilization under current regulatory framework. Changes in medical/insurance systems, data privacy regulations, pharmaceutical marketing regulations, or reimbursement policies could materially impact customer demand, data access rights, and business viability. The company operates in a highly regulated sector where policy shifts can rapidly alter market dynamics.

Key Takeaways from Earnings

(1) High-Margin Growth Business with Capital Efficiency Challenge: The company demonstrates exceptional profit margins (Operating Margin 21.3% vs. industry median 8.0%, Net Margin 13.2% vs. 5.6%) and strong revenue growth (+23.2% vs. industry median +10.5%), confirming a differentiated, high-value-added business model in healthcare data analytics. However, ROE of 5.8% (vs. industry median 8.2%) and ROIC of 4.1% (vs. industry median 16.0%) indicate capital efficiency significantly lags industry, primarily due to goodwill-heavy balance sheet (634.4B yen) and low asset turnover (0.234 vs. median 0.68). The key observation is that profitability from operations is strong, but M&A-driven growth strategy has not yet translated into commensurate returns on invested capital.

(2) Strong Cash Generation Offset by Aggressive Investment Posture: Operating cash flow of 56.0B yen exceeded net income (1.16x ratio), confirming high-quality cash-backed earnings from core operations. However, FCF is negative 21.4B yen due to 77.4B yen investing cash outflow including 63.1B yen subsidiary acquisition. This indicates the company is in active investment phase, prioritizing growth over near-term cash returns. The sustainability of this strategy depends on investment returns materializing—current ROIC of 4.1% suggests returns are delayed. With cash reserves of 302.4B yen and manageable debt (Net Debt/EBITDA approximately 1.3x), financial flexibility exists to continue investments, but efficiency improvement is critical for long-term value creation.

(3) Structural Working Capital Issue Requires Monitoring: Accounts receivable DSO of approximately 200 days (vs. industry median 60.53 days) represents a significant structural weakness in cash conversion cycle. While operating CF currently remains healthy, the extended collection period ties up substantial capital, increases credit risk exposure, and constrains financial flexibility. This is flagged in quality alerts and represents a material operational risk. Improvement in receivables collection efficiency would materially enhance cash generation capacity and reduce working capital burden. The trend and management actions on this metric are critical factors for assessing operational execution quality and cash flow sustainability.

---

This report was automatically generated by AI integrating XBRL earnings data and PDF presentation materials as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.

---

AI Analysis (Earnings Presentation)

AI analysis of PDF earnings presentation

Summary

For the cumulative period through Q3 of FY March 2026, JMDC delivered solid results with consolidated revenue of 36,488 million yen (+23% YoY) and consolidated EBITDA of 9,682 million yen (+27% YoY). The core Health Big Data segment led high growth with revenue +26% and EBITDA +32%. Industry-facing data utilization grew +30% centered on sales and marketing for pharmaceutical companies, and healthcare provider-facing also performed well at +32%. The Telemedicine segment posted revenue +5% and EBITDA +6%, maintaining high profitability (EBITDA margin 38%). In Q3, the company recovered from the Q2 deceleration and returned to a robust growth trajectory. Management assessed progress as on track toward achieving full-year guidance, highlighting the proliferation of generative AI, expanding data demand, and strategic partnerships with electronic medical record (EMR) vendors as growth opportunities.

Key Highlights

The Health Big Data segment achieved high growth with revenue +26% YoY and EBITDA +32%, with profitability also improving. Transaction value of data utilization in sales and marketing for pharmaceutical companies expanded strongly at +43% YoY. In Q3 standalone, consolidated revenue was 13,407 million yen (+21% QoQ) and EBITDA 4,157 million yen (+32% QoQ), making the recovery trend clear. Announced strategic partnerships with EMR vendors to accelerate the build-out of a dominant foundation of provider-derived data. Projecting that advancement in generative AI will accelerate the hypothesis-testing cycle and relatively increase demand for objective data.

Business Outlook

Momentum across the business remains solid toward achieving full-year guidance. Robust demand persists in sales and marketing for pharmaceutical companies, sustaining strong growth. While progress in leveraging new senior (elderly) data in the Medical domain was delayed, recent bookings are trending upward with a re-acceleration expected. The life insurance business is recovering from softness in the first half, and growth momentum heading into the next fiscal year is steadily strengthening. For insurers and consumers, the data platform continues to expand steadily, and the healthcare provider-facing business is also growing well, centered on high value-added offerings.

Management Guidance

Management characterized Q3 results as a “return to the company’s inherently strong growth trajectory.” Concerns about the sense of deceleration in Q2 were alleviated by re-acceleration in Q3. New data initiatives and efficiency gains in the Health Big Data segment contributed to profit growth outpacing revenue growth. The company reaffirmed its commitment to achieving full-year guidance. It views generative AI and consolidation within the health tech industry as positive opportunities and expressed expectations for outcomes from EMR integrations from next fiscal year onward.

Strategic Initiatives

Strengthen provider-derived data through strategic partnerships with EMR vendors to build an unparalleled data foundation. Leverage increased data demand accompanying the broader use of generative AI as a tailwind, supporting more advanced customer decision-making. Deploy high value-added consulting and data/AI solutions for sales and marketing divisions of pharmaceutical companies. Promote proposals for insurers utilizing new data such as senior (elderly) datasets to drive re-acceleration. Capitalize on consolidation trends in the health tech space by proactively partnering with truly value-accretive partners.

Reference Assumptions

• Other: Full-year EBITDA margin target of 29%. Demand in sales and marketing for pharmaceutical companies remains strong; the Medical domain is expected to re-accelerate on increasing bookings. For insurers, data platform expansion continues. Telemedicine assumes continued stable demand.

Disclosed Risks

Delay in progress utilizing senior (elderly) data in the Medical division (bookings are trending up with recovery expected). Temporary deceleration observed in Q2 (recovered in Q3). Softness in the life insurance business in the first half (currently recovering). Privatizations and M&A-driven consolidation trends in health tech (assessed to have limited impact on the company’s performance). Acceleration of the hypothesis-testing cycle as generative AI advances, leading to a relative increase in demand for data-backed validation (both an opportunity and a risk).

---

AI Financial Analysis

Executive Summary

JMDC delivered a strong FY2026 Q3 cumulative earnings performance, with revenue growth of 23.2% YoY and operating-income growth of 37.1% YoY. Revenue reached ¥36.49bn, while operating income increased to ¥7.77bn. Net income attributable to owners rose 24.6% YoY to ¥4.81bn. Operating margin expanded by 220bp YoY to 21.3%, calculated from the reported revenue and operating-income figures. Gross margin was 54.8%, reflecting a high value-added business mix. EBITDA rose to ¥10.10bn and the EBITDA margin was 27.7%, supporting the underlying earnings capacity of the platform and healthcare-data businesses. Net profit margin was 13.2%, which remains excellent relative to the stated 10% benchmark. The operating-profit growth rate exceeded revenue growth by 13.9 percentage points, indicating favorable operating leverage despite SG&A increasing 13.5% YoY to ¥12.65bn. Profit before tax grew 32.1% YoY, but the effective tax rate rose to 34.1% from approximately 31.6% in the prior-year period, limiting net-income growth relative to operating-income growth. Cash earnings were positive: operating cash flow was ¥5.60bn and equaled 1.16x net income. However, operating cash flow declined from ¥10.74bn in the prior-year period because working-capital support was less favorable and cash taxes paid increased to ¥4.14bn. Investing cash outflow of ¥7.74bn was led by ¥6.31bn of subsidiary acquisitions, resulting in reported free cash flow of negative ¥2.14bn. The balance sheet remains equity-funded overall, with a 52.4% equity ratio and debt-to-equity of 0.89x, but acquisition-related leverage is elevated at 4.22x debt/EBITDA. Goodwill of ¥63.44bn represents 77.0% of equity and 40.6% of assets, making future acquisition integration and impairment testing central to the risk profile. Against FY2026 guidance, Q3 progress is 72.3% for revenue, 67.5% for operating income, and 64.1% for net income, each below the typical 75% Q3 run rate. The company therefore requires a notably stronger Q4, particularly at the profit level, to achieve its full-year targets. Overall, the results show robust top-line momentum, margin expansion and acceptable operating cash conversion versus net income, offset by M&A-funded capital-allocation risk, high goodwill concentration and a back-end-loaded guidance profile.

Profitability Analysis

The reported annualized DuPont ROE is 7.8%, comprising a 13.2% net profit margin, 0.311x annualized asset turnover and 1.89x financial leverage. The principal constraint on ROE is asset turnover rather than margin: JMDC generates a high net margin but carries a substantial asset base, notably ¥63.44bn of goodwill and ¥18.58bn of PPE. Financial leverage is moderate at 1.89x and contributes to shareholder returns without breaching the 2.0x D/E warning threshold; reported D/E is 0.89x. Margin was the key positive driver during the period. Operating margin widened from approximately 19.1% in FY2025 Q3 to 21.3% in FY2026 Q3, a 220bp expansion, as operating income rose 37.1% against revenue growth of 23.2%. Gross margin increased from approximately 56.7% to 54.8%, a 190bp contraction, but SG&A fell from approximately 37.6% to 34.7% of revenue, more than offsetting gross-margin pressure. SG&A expanded 13.5% YoY, materially below revenue growth, demonstrating positive operating leverage. EBITDA margin of 27.7% provides an additional indication of strong pre-depreciation profitability under IFRS. Finance costs of ¥0.51bn reduced EBIT by 5.9%, as shown by the 0.941 interest burden; this remains manageable but is relevant given the elevated debt/EBITDA ratio. The tax burden was 0.658, below the 0.70 benchmark, because the 34.1% effective tax rate absorbed a larger portion of pretax profit. The quality of margin expansion will depend on whether the lower SG&A intensity can be maintained while the company continues acquisition integration and invests in data, systems and customer coverage.

Growth Assessment

Revenue increased ¥6.87bn YoY to ¥36.49bn, or 23.2%, demonstrating continued expansion across the consolidated business base. Operating income increased by ¥2.10bn, or 37.1%, faster than sales, confirming that growth was not solely acquisition-driven revenue expansion but also translated into improved operating profitability. Net income attributable to owners increased by ¥0.95bn to ¥4.81bn, or 24.6%; its slower growth than operating income primarily reflects higher finance costs and a higher effective tax rate. The Q3 cumulative operating margin of 21.3% is 220bp above the prior-year period, while EBITDA margin is 27.7%. FY2026 full-year guidance calls for revenue of ¥50.50bn, operating income of ¥11.50bn and net income attributable to owners of ¥7.40bn. Q3 progress versus guidance is 72.3% for revenue, 67.5% for operating income and 64.1% for owner-attributable net income, versus a standard 75% cumulative Q3 benchmark. This implies required Q4 revenue of ¥14.01bn, operating income of ¥3.73bn and owner-attributable net income of ¥2.59bn. Required Q4 operating margin is approximately 26.6%, above the Q3 cumulative 21.3% margin, so the profit guidance assumes a meaningful sequential improvement. Acquisitions consumed ¥6.31bn of investing cash flow and contributed to the increase in goodwill, indicating that inorganic growth remains an important component of the growth model. Sustained organic monetization of healthcare and data assets, successful post-merger integration, and retention of current SG&A discipline are therefore important to maintaining the current earnings trajectory.

Financial Health

Liquidity appears sound on reported balance-sheet figures. Current assets were ¥57.74bn, while implied current liabilities were ¥24.74bn, producing a calculated current ratio of approximately 2.33x; this is comfortably above the 1.0x warning threshold. Cash and cash equivalents of ¥30.24bn exceeded short-term loans of ¥5.59bn by approximately 5.4x, so the reported balance-sheet amounts do not indicate a near-term cash-versus-short-term-loan maturity mismatch. Current lease liabilities of ¥1.29bn and accounts payable of ¥12.04bn should nevertheless be considered alongside short-term loans when assessing operational liquidity. Total interest-bearing debt was ¥42.64bn, consisting of ¥5.59bn in short-term loans and ¥37.05bn in long-term loans; 13.1% of debt is short term, which limits refinancing concentration in the immediate term. Debt-to-equity was 0.89x and debt-to-capital was 34.1%, both within the stated conservative or investment-grade reference ranges. However, debt/EBITDA was 4.22x, above the 4.0x high-leverage threshold, and is the principal financial-structure concern. This leverage is meaningful in an acquisitive company because it reduces flexibility if acquired businesses underperform or if funding costs rise. Finance costs rose to ¥0.51bn from ¥0.15bn in the prior-year period, consistent with a higher debt burden and/or higher financing costs. Goodwill was ¥63.44bn, equivalent to 77.0% of equity, substantially above the 50% warning level. Goodwill also accounted for 40.6% of total assets, while PPE increased ¥4.65bn, or 33.4% YoY, to ¥18.58bn. The goodwill concentration means that a material part of book equity depends on the continuing earnings performance of acquired businesses. Accounts payable increased ¥4.29bn, or 55.4% YoY, to ¥12.04bn, which supported operating cash flow but should be monitored for normalization. Inventories increased 57.9% YoY to ¥0.57bn, though inventories remain only 0.4% of total assets and are not a material balance-sheet risk. Short-term loans rose 27.2% YoY to ¥5.59bn, reinforcing the need to preserve cash generation and refinancing capacity. Lease liabilities totalled ¥10.00bn, representing an additional fixed contractual obligation beyond loans.

Notable B/S Changes

Goodwill: +¥5.03bn (+8.6%) to ¥63.44bn - acquisition-led asset concentration remains high at 77.0% of equity; integration performance and impairment testing are critical. PPE: +¥4.65bn (+33.4%) to ¥18.58bn - expanded fixed-asset base may support operating capacity, but requires adequate utilization and renewal investment. Accounts payable: +¥4.29bn (+55.4%) to ¥12.04bn - provided a ¥3.79bn operating-cash-flow benefit; normalization could reduce future cash conversion. Short-term loans: +¥1.20bn (+27.2%) to ¥5.59bn - short-term borrowing increased, although cash of ¥30.24bn and a 13.1% short-term debt ratio mitigate immediate maturity risk. Inventories: +¥0.21bn (+57.9%) to ¥0.57bn - growth rate is high but the balance remains immaterial at 0.4% of total assets. Long-term loans: +¥3.17bn (+9.4%) to ¥37.05bn - absolute increase supports acquisition financing and contributes to elevated 4.22x debt/EBITDA.

Cash Flow Quality

Operating cash flow was ¥5.60bn, equal to 1.16x net income of ¥4.81bn, exceeding the 1.0x high-quality earnings threshold. The accruals ratio was negative 0.5%, also consistent with relatively sound accounting earnings conversion. Cash conversion measured as operating cash flow/EBITDA was 0.55x, below the 0.7x warning threshold and requiring attention despite the favorable OCF/net-income ratio. The difference arises because EBITDA of ¥10.10bn was reduced by ¥4.14bn in cash taxes, ¥0.94bn in lease payments and other cash-flow items. Working capital contributed positively overall, led by a ¥3.79bn increase in payables and a ¥0.76bn source from receivables. The favorable payable movement is substantially larger than the prior-year ¥1.74bn contribution and should not be assumed to recur at the same rate. Receivables were ¥19.99bn, and the quality alert identifies annualized DSO of 150 days, well above the 60-day benchmark. This elevated collection cycle is a material working-capital risk: slower customer collections could reverse the current-period receivables cash contribution and pressure operating cash flow. Inventory cash usage was modest at ¥0.19bn and the absolute inventory balance remains low. Reported free cash flow was negative ¥2.14bn because investing cash outflows of ¥7.74bn exceeded operating cash flow. The primary use of cash was ¥6.31bn for acquisitions of subsidiaries, supplemented by ¥1.05bn in intangible-asset purchases and ¥0.41bn in capex. On a narrow operating definition of OCF less reported capex, pre-acquisition free cash flow was positive at approximately ¥5.19bn; hence the negative reported FCF is primarily a capital-allocation and acquisition effect rather than a weakness in core cash generation. Capex/depreciation was only 0.17x, below the 0.7x underinvestment warning threshold. For an IT and healthcare-data business, modest tangible capex can be structurally appropriate, but capex alone understates reinvestment because intangible purchases were ¥1.05bn; nevertheless, continued low replacement investment relative to depreciation warrants monitoring for technology, systems and infrastructure renewal. The low-cash-conversion alert is therefore a cash-timing and reinvestment-quality issue rather than evidence that reported net income lacks immediate operating-cash support.

Dividend Sustainability

Dividends paid during the nine-month period were ¥1.05bn. Relative to net income attributable to owners of ¥4.81bn, the implied cumulative cash dividend payout ratio was approximately 21.7%, which is conservatively below the 60% sustainability benchmark. Dividends were covered by operating cash flow of ¥5.60bn by approximately 5.4x. They were also covered by narrow pre-acquisition free cash flow of approximately ¥5.19bn by approximately 5.0x. Reported free cash flow, including acquisition investing cash flow, was negative ¥2.14bn, so dividends are not covered after the full acquisition program in the current period. This does not indicate immediate dividend stress given the ¥30.24bn cash balance and the low payout ratio, but it demonstrates that shareholder distributions compete with M&A outlays and debt management for capital. The disclosed Q2 DPS was ¥0, while dividends paid confirm that cash distributions occurred during the period; the reported figures support analysis of aggregate cash payout rather than a precise current-period DPS payout ratio. No share repurchases were reported, so total return equals the dividend distribution for the period. Dividend capacity should remain supported if operating cash flow is sustained and acquisition spending normalizes, whereas aggressive M&A or a rise in financing costs would reduce flexibility.

Risk Assessment

Business risks include Acquisition integration risk is high: ¥6.31bn was spent on subsidiary acquisitions during the period and goodwill reached ¥63.44bn. Failure to achieve planned revenue synergies, cost efficiencies or customer retention could weaken margins and cash generation., Healthcare-data and IT service businesses face data-security, privacy, system-availability and regulatory-compliance risk. A security incident or a tightening of data-use requirements could damage customer confidence and constrain data monetization., High receivable days of 150 days create collection and customer-credit risk. Although receivables declined modestly YoY, the collection cycle remains materially above the 60-day benchmark., The full-year profit plan is back-end loaded. Required Q4 operating margin of approximately 26.6% is above the FY2026 Q3 cumulative margin of 21.3%, increasing execution risk..

Financial risks include Debt/EBITDA of 4.22x exceeds the 4.0x high-leverage benchmark. This makes earnings volatility, refinancing conditions and interest-rate increases more consequential., Goodwill/equity of 77.0% is substantially above the 50% warning level. Any impairment would directly reduce equity and could adversely affect leverage metrics., Finance costs increased to ¥0.51bn from ¥0.15bn YoY. The interest burden remains acceptable at 0.941, but debt costs should be monitored as long-term loans are ¥37.05bn., Operating cash flow relied materially on a ¥3.79bn increase in payables. Reversal of this working-capital benefit could reduce cash conversion., The liquidity-stress quality alert should be monitored, but it is not corroborated by the reported cash and short-term-loan balances: cash of ¥30.24bn is approximately 5.4x short-term loans of ¥5.59bn, and the calculated current ratio is approximately 2.33x..

Key concerns include Highest priority: goodwill concentration and acquisition execution, because ¥63.44bn of goodwill equals 40.6% of assets and 77.0% of equity., High priority: leverage at 4.22x debt/EBITDA, particularly if further acquisitions are debt funded or EBITDA growth slows., High priority: collection-cycle discipline, as the 150-day DSO alert points to potential cash-flow volatility despite current-period OCF exceeding net income., Medium priority: low cash conversion of 0.55x OCF/EBITDA. The root cause is substantial cash taxes, lease payments and working-capital effects; its impact is reduced internal funding capacity for acquisitions, debt reduction and dividends., Medium priority: capex/depreciation of 0.17x. The root cause is low reported tangible capex relative to depreciation; intangible purchases partly mitigate the concern, but persistent underinvestment could affect service capacity, technology renewal and future growth., Medium priority: Q3 guidance progress below the 75% seasonal benchmark, particularly operating-income progress at 67.5% and net-income progress at 64.1%..

Investment Implications

Key takeaways include Revenue growth of 23.2% and operating-income growth of 37.1% demonstrate strong operating momentum and favorable SG&A leverage., Operating margin expanded 220bp YoY to 21.3%, while EBITDA margin reached 27.7%, placing profitability above the stated excellence benchmarks., The annualized 7.8% ROE is restrained by low asset turnover associated with the acquisition-built asset base rather than weak margins., OCF/net income of 1.16x and a negative 0.5% accruals ratio support earnings quality, but 0.55x OCF/EBITDA and 150-day DSO warrant close cash-conversion monitoring., The company has adequate reported short-term liquidity, but debt/EBITDA of 4.22x and goodwill/equity of 77.0% make deleveraging, acquisition discipline and impairment avoidance strategically important., FY2026 guidance requires a stronger Q4, with implied operating margin of approximately 26.6% on the remaining sales target..

Metrics to watch include Q4 revenue, operating-income and owner-attributable net-income delivery versus ¥50.50bn, ¥11.50bn and ¥7.40bn respective FY2026 guidance, Operating margin versus the 21.3% FY2026 Q3 cumulative level and the approximately 26.6% implied Q4 requirement, Debt/EBITDA, long-term loan balance and finance-cost trend, Goodwill balance, acquisition spending, post-acquisition earnings contribution and impairment charges, DSO, accounts receivable collection, payables movement and OCF/EBITDA conversion, Tangible capex plus intangible investment relative to depreciation and growth requirements.

Regarding relative positioning, JMDC combines high margins and strong revenue growth with an acquisition-intensive balance sheet. Its 21.3% operating margin, 13.2% net margin and 27.7% EBITDA margin are strong for a healthcare-data and IT-oriented platform, while the 7.8% annualized ROE is comparatively modest because goodwill and other acquisition-related assets suppress asset turnover. Relative financial positioning is therefore characterized by attractive operating economics but a more demanding capital-allocation and balance-sheet risk profile than a similarly profitable organically grown, lower-goodwill peer.